MUC1 and metastatic cancer: Expression, function and therapeutic targeting

Cell Adhesion and Migration

Volumn 7, Issue 2, 2013, Pages 187-198

  Horm, Teresa M ^a   Schroeder, Joyce A ^a  

^a University of Arizona   (United States)

Author keywords

Adhesion; Invasion; Metastasis; Migration; MUC1

Indexed keywords

ABELSON KINASE; ANTIGEN; BM 7 ANTIGEN; CA 15-3 ANTIGEN; CANCER VACCINE; COMPLEMENTARY DNA; GROWTH FACTOR RECEPTOR; KL 6 ANTIGEN; MICRORNA; MUCIN 1; PROTEIN BAX; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER GROWTH; CELL INTERACTION; CELL NUCLEUS MEMBRANE; CIRCULATING TUMOR CELL; CYTOPLASM; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; LUNG METASTASIS; METASTASIS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW;

EID: 84878463053     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.23131     Document Type: Review

References (127)

1. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12: 895-904; PMID:16892035; http://dx.doi.org/10.1038/nm1469
2. Baldus SE, Engelmann K, Hanisch FG. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 2004; 41: 189-231; PMID:15270554; http://dx.doi.org/10.1080/10408360490452040
3. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001; 6: 339-53; PMID:11547902; http://dx.doi.org/10.1023/A: 1011379725811
4. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010; 29: 2893-904; PMID:20348949; http://dx.doi.org/10.1038/onc.2010.87
5. Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2012; In press; PMID:22580612; http://dx.doi.org/10.1038/onc.2012.158
6. Singh PK, Hollingsworth MA. Cell surface-associated mucins in signal transduction. Trends Cell Biol 2006; 16: 467-76; PMID:16904320; http://dx.doi.org/10.1016/j.tcb.2006.07.006
7. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001; 91: 1973-82; PMID:11391575; http://dx.doi.org/10.1002/1097-0142 (20010601)91:11〈1973:: AIDCNCR1222〉3.0.CO;2-A
8. Lavrsen K, Madsen CB, Rasch MG, Woetmann A, Odum N, Mandel U, et al. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J 2012; In press; PMID:22878593; http://dx.doi.org/10.1007/s10719-012-9437-7
9. McGuckin MA, Walsh MD, Hohn BG, Ward BG, Wright RG. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 1995; 26: 432-9; PMID:7705823; http://dx.doi.org/10.1016/0046-8177(95)90146-9
10. Greenberg R, Barnea Y, Schneebaum S, Kashtan H, Kaplan O, Skornik Y. Detection of hepatocyte growth factor/scatter factor receptor (c-Met) and MUC1 from the axillary fluid drainage in patients after breast cancer surgery. Isr Med Assoc J 2003; 5: 649-52; PMID:14509156.
11. Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 2003; 22: 1324-32; PMID:12618757; http://dx.doi.org/10.1038/sj.onc. 1206291
12. Park S, Ahn HK, Park LC, Hwang DW, Ji JH, Maeng CH, et al. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer. Oncology 2012; 82: 180-7; PMID:22433564; http://dx.doi.org/10.1159/000336081
13. Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, et al. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother 2011; 60: 975-84; PMID:21461842; http://dx.doi.org/10.1007/s00262-011-1010-x
14. Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, et al. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol 2007; 105: 695-702; PMID:17368732; http://dx.doi.org/10.1016/j.ygyno.2007.02.004
15. Dong Y, Walsh MD, Cummings MC, Wright RG, Khoo SK, Parsons PG, et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 1997; 183: 311-7; PMID:9422987; http://dx.doi.org/10.1002/(SICI)1096-9896(199711)183: 3〈311: :AIDPATH917〉3.0.CO;2-2
16. Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ, et al. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 2005; 22: 565-73; PMID:16475027; http://dx.doi.org/10.1007/s10585-005-5376-z
17. Retterspitz MF, Mönig SP, Schreckenberg S, Schneider PM, Hölscher AH, Dienes HP, et al. Expression of beta-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Res 2010; 30: 4635-41; PMID:21115917.
18. Yonezawa S, Kitajima S, Higashi M, Osako M, Horinouchi M, Yokoyama S, et al. A novel anti-MUC1 antibody against the MUC1 cytoplasmic tail domain: use in sensitive identification of poorly differentiated cells in adenocarcinoma of the stomach. Gastric Cancer 2012; 15: 370-81; PMID:22237656; http://dx.doi.org/10. 1007/s10120-011-0125-2
19. Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Yoshitomi H, et al. Similarities and differences between intraductal papillary tumors of the bile duct with and without macroscopically visible mucin secretion. Am J Surg Pathol 2011; 35: 512-21; PMID:21412069; http://dx.doi.org/10.1097/PAS.0b013e3182103f36
20. Zhang K, Tang W, Qu X, Guo Q, Inagaki Y, Seyama Y, et al. KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma. Hepatogastroenterology 2009; 56: 960-3; PMID:19760920.
21. Mizumoto M, Honjo G, Kobashi Y, Awane M, Matsusue S. Molecular profile of apomucin and p53 protein as predictors of malignancy in intraductal papillary mucinous neoplasms of the pancreas. Hepatogastroenterology 2011; 58: 1791-5; PMID:22086702.
22. Xu H, Inagaki Y, Seyama Y, Du G, Wang F, Kokudo N, et al. Expression of KL-6/MUC1 in pancreatic cancer tissues and its potential involvement in tumor metastasis. Oncol Rep 2011; 26: 371-6; PMID:21617869.
23. Hamada T, Nomura M, Kamikawa Y, Yamada N, Batra SK, Yonezawa S, et al. DF3 epitope expression on MUC1 mucin is associated with tumor aggressiveness, subsequent lymph node metastasis, and poor prognosis in patients with oral squamous cell carcinoma. Cancer 2012; 118: 5251-64; PMID:22434549; http://dx.doi.org/10.1002/cncr.27542
24. Liu XY, Chen G, Wang Z, Liu FY. Clinical significance of detecting mucin 1 mRNA in diagnosing occult lymph node micrometastasis in esophageal cancer patients. Ai Zheng 2007; 26: 194-9; PMID:17298752.
25. Leroy X, Zerimech F, Zini L, Copin MC, Buisine MP, Gosselin B, et al. MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma. Am J Clin Pathol 2002; 118: 47-51; PMID:12109855; http://dx.doi.org/10.1309/1F99-BPDY-7DHH-9G97
26. Hasegawa H, Komoda M, Yamada Y, Yonezawa S, Tsutsumida H, Nagai K, et al. Aberrant overexpression of membrane-associated mucin contributes to tumor progression in adult T-cell leukemia/lymphoma cells. Leuk Lymphoma 2011; 52: 1108-17; PMID:21599593; http://dx.doi.org/10.3109/10428194.2011.559671
27. Kaira K, Murakami H, Serizawa M, Koh Y, Abe M, Ohde Y, et al. MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma. Virchows Arch 2011; 458: 615-20; PMID:21253760; http://dx.doi.org/10.1007/s00428-011- 1041-x
28. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 2012; 9: 016003; PMID:22306768; http://dx.doi.org/10.1088/ 1478-3975/9/1/016003
29. Sanislo L, Vertakova-Krakovska B, Kuliffay P, Brtko J, Galbava A, Galbavy S. Detection of circulating tumor cells in metastatic breast cancer patients. Endocr Regul 2011; 45: 113-24; PMID:21793623; http://dx.doi.org/10.4149/endo- 2011-03-113
30. Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke JF. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res 2008; 10: R69; PMID:18687126; http://dx.doi.org/10.1186/bcr2131
31. Sha MY, Xu H, Natan MJ, Cromer R. Surface-enhanced Raman scattering tags for rapid and homogeneous detection of circulating tumor cells in the presence of human whole blood. J Am Chem Soc 2008; 130: 17214-5; PMID:19053187; http://dx.doi.org/10.1021/ja804494m
32. de Albuquerque A, Kaul S, Breier G, Krabisch P, Fersis N. Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine. Breast Care (Basel) 2012; 7: 7-12; PMID:22553466; http://dx.doi.org/10.1159/000336548
33. de Albuquerque A, Kubisch I, Breier G, Stamminger G, Fersis N, Eichler A, et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology 2012; 82: 3-10; PMID:22270149; http://dx.doi.org/10.1159/000335479
34. de Albuquerque A, Kubisch I, Ernst D, Breier G, Stamminger G, Fersis N, et al. Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients. Clin Lab 2012; 58: 373-84; PMID:22783565.
35. Aktas B, Müller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 2011; 122: 356-60; PMID:21605893; http://dx.doi.org/10.1016/j.ygyno.2011. 04.039
36. Thie H, Toleikis L, Li J, von Wasielewski R, Bastert G, Schirrmann T, et al. Rise and fall of an anti- MUC1 specific antibody. PLoS One 2011; 6: e15921; PMID:21264246; http://dx.doi.org/10.1371/journal.pone.0015921
37. Kruit A, Gerritsen WB, Pot N, Grutters JC, van den Bosch JM, Ruven HJ. CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27: 138-46; PMID:21319596.
38. Duffy MJ, Shering S, Sherry F, McDermott E, O'Higgins N. CA 15-3: a prognostic marker in breast cancer. Int J Biol Markers 2000; 15: 330-3; PMID:11192829.
39. González-Sistal A, Arias JI, Ruibal A. CA 15-3 serum levels in patients with ductal breast carcinoma: relationship with clinicopathological parameters and tumor markers. Int J Biol Markers 2012; 27: 47-52; PMID:21928245; http://dx.doi.org/10.5301/JBM.2011.8591
40. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, et al. Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol 2006; 12: 54-9; PMID:16440417.
41. Kaira K, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, et al. Depolarized MUC1 expression is closely associated with hypoxic markers and poor outcome in resected non-small cell lung cancer. Int J Surg Pathol 2012; 20: 223-32; PMID:22108499; http://dx.doi.org/10.1177/1066896911429296
42. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005; 18: 1295-304; PMID:15976813; http://dx.doi.org/10.1038/modpathol.3800445
43. Ghosh M, Kamma H, Kawamoto T, Koike N, Miwa M, Kapoor VK, et al. MUC 1 core protein as a marker of gallbladder malignancy. Eur J Surg Oncol 2005; 31: 891-6; PMID:15922536; http://dx.doi.org/10.1016/j.ejso.2005.03.008
44. Spicer AP, Rowse GJ, Lidner TK, Gendler SJ. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem 1995; 270: 30093-101; PMID:8530414; http://dx.doi.org/10.1074/jbc.270.50.30093
45. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12: 954-61; PMID:1312220.
46. Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, Thompson MC, et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004; 23: 5739-47; PMID:15221004; http://dx.doi.org/10.1038/sj.onc.1207713
47. Sandgren EP, Schroeder JA, Qui TH, Palmiter RD, Brinster RL, Lee DC. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res 1995; 55: 3915-27; PMID:7641211.
48. Pochampalli MR, Bitler BG, Schroeder JA. Transforming growth factor alpha dependent cancer progression is modulated by Muc1. Cancer Res 2007; 67: 6591-8; PMID:17638868; http://dx.doi.org/10.1158/0008-5472.CAN-06-4518
49. Besmer DM, Curry JM, Roy LD, Tinder TL, Sahraei M, Schettini J, et al. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res 2011; 71: 4432-42; PMID:21558393; http://dx.doi.org/10.1158/0008-5472.CAN-10-4439
50. Finn OJ, Gantt KR, Lepisto AJ, Pejawar-Gaddy S, Xue J, Beatty PL. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunol Res 2011; 50: 261-8; PMID:21717081; http://dx.doi.org/10.1007/s12026-011-8214-1
51. Rye PD, Norum L, Olsen DR, Garman-Vik S, Kaul S, Fodstad O. Brain metastasis model in athymic nude mice using a novel MUC1-secreting human breast-cancer cell line, MA11. Int J Cancer 1996; 68: 682-7; PMID:8938153; http://dx.doi.org/10.1002/(SICI)1097-0215(19961127)68:5〈682:: AIDIJC20〉3.0.CO;2-2
52. Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, et al. MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol 2009; 35: 337-45; PMID:19578748.
53. Tsutsumida H, Swanson BJ, Singh PK, Caffrey TC, Kitajima S, Goto M, et al. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin Cancer Res 2006; 12: 2976-87; PMID:16707592; http://dx.doi.org/10.1158/1078-0432.CCR-05-1197
54. Aubert S, Fauquette V, Hémon B, Lepoivre R, Briez N, Bernard D, et al. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res 2009; 69: 5707-15; PMID:19549898; http://dx.doi.org/10.1158/0008-5472.CAN-08-4905
55. Mikami Y, Hisatsune A, Tashiro T, Isohama Y, Katsuki H. Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line. Biochem Biophys Res Commun 2009; 379: 1060-5; PMID:19141292; http://dx.doi.org/10.1016/j.bbrc.2009.01.002
56. Gaemers IC, Vos HL, Volders HH, van der Valk SW, Hilkens J. A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem 2001; 276: 6191-9; PMID:11084045; http://dx.doi.org/10.1074/jbc.M009449200
57. Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E, Smith PD. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol 2001; 19: 1155-60; PMID:11713584.
58. Xia L, Wang L, Chung AS, Ivanov SS, Ling MY, Dragoi AM, et al. Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem 2002; 277: 30716-23; PMID:12070153; http://dx.doi.org/10.1074/jbc.M202823200
59. Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C, et al. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 2010; 29: 920-9; PMID:19915608; http://dx.doi.org/10. 1038/onc.2009.391
60. Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007; 26: 1693-701; PMID:16983337; http://dx.doi.org/10.1038/sj.onc.1209976
61. Li Y, Kuwahara H, Ren J, Wen G, Kufe D. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem 2001; 276: 6061-4; PMID:11152665; http://dx.doi.org/10.1074/jbc.C000754200
62. Rajabi H, Joshi MD, Jin C, Ahmad R, Kufe D. Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells. Prostate 2011; 71: 1299-308; PMID:21308711.
63. Mitchell S, Abel P, Madaan S, Jeffs J, Chaudhary K, Stamp G, et al. Androgen-dependent regulation of human MUC1 mucin expression. Neoplasia 2002; 4: 9-18; PMID:11922395; http://dx.doi.org/10.1038/sj.neo.7900194
64. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 2010; 201: 102-10; PMID:20682394; http://dx.doi.org/10.1016/j.cancergencyto.2010.05.015
65. Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD, Kufe D. MUCIN 1 ONCOPROTEIN EXPRESSION IS SUPPRESSED BY THE miR-125b ONCOMIR. Genes Cancer 2010; 1: 62-8; PMID:20729973; http://dx.doi.org/10.1177/1947601909357933
66. O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010; 12: 201; PMID:20346098; http://dx.doi.org/10. 1186/bcr2484
67. Sachdeva M, Mo YY. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res 2010; 2: 170-80; PMID:20407606.
68. Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol Biomarkers Prev 2011; 20: 1272-86; PMID:21551242; http://dx.doi.org/10.1158/1055-9965.EPI-11-0035
69. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 1996; 56: 4244-9; PMID:8797599.
70. Ciborowski P, Finn OJ. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clin Exp Metastasis 2002; 19: 339-45; PMID:12090474; http://dx.doi.org/10.1023/A: 1015590515957
71. Geng Y, Yeh K, Takatani T, King MR. Three to Tango: MUC1 as a Ligand for Both E-Selectin and ICAM-1 in the Breast Cancer Metastatic Cascade. Front Oncol 2012; 2: 76; PMID:22866263; http://dx.doi.org/10.3389/fonc.2012.00076
72. Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance DM. Interactions between cancer cells and the endothelium in metastasis. J Pathol 2000; 190: 310-29; PMID:10685065; http://dx.doi.org/10.1002/(SICI)1096-9896(200002)190: 3〈310: :AIDPATH525〉3.0.CO;2-P
73. Shen Q, Rahn JJ, Zhang J, Gunasekera N, Sun X, Shaw AR, et al. MUC1 initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal protrusive motility after ligating intercellular adhesion molecule-1. Mol Cancer Res 2008; 6: 555-67; PMID:18403635; http://dx.doi.org/10.1158/1541-7786.MCR-07-2033
74. Rahn JJ, Chow JW, Horne GJ, Mah BK, Emerman JT, Hoffman P, et al. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis 2005; 22: 475-83; PMID:16320110; http://dx.doi.org/10.1007/s10585-005-3098-x
75. Aleshin A, Finn RS. SRC: a century of science brought to the clinic. Neoplasia 2010; 12: 599-607; PMID:20689754.
76. Horn G, Gaziel A, Wreschner DH, Smorodinsky NI, Ehrlich M. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp Cell Res 2009; 315: 1490-504; PMID:19245809; http://dx.doi.org/10.1016/j.yexcr.2009.02.011
77. Yao M, Zhang W, Zhang Q, Xing L, Xu A, Liu Q, et al. Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways. Lung 2011; 189: 453-60; PMID:21959954; http://dx.doi.org/10.1007/s00408-011-9327-y
78. Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X, et al. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A 2012; 109: 13787-92; PMID:22869720; http://dx.doi.org/10.1073/pnas.1203339109
79. Grosfeld A, Andre J, Hauguel-De Mouzon S, Berra E, Pouyssegur J, Guerre-Millo M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem 2002; 277: 42953-7; PMID:12215445; http://dx.doi.org/10. 1074/jbc.M206775200
80. Scheid A, Wenger RH, Schäffer L, Camenisch I, Distler O, Ferenc A, et al. Physiologically low oxygen concentrations in fetal skin regulate hypoxia-inducible factor 1 and transforming growth factor-beta3. FASEB J 2002; 16: 411-3; PMID:11790723.
81. Woo JK, Choi Y, Oh SH, Jeong JH, Choi DH, Seo HS, et al. Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway. Oncogene 2012; 31: 2187-98; PMID:21927028; http://dx.doi.org/10.1038/onc.2011. 410
82. Litvinov SV, Hilkens J. The epithelial sialomucin, episialin, is sialylated during recycling. J Biol Chem 1993; 268: 21364-71; PMID:8407976.
83. Marti U, Burwen SJ, Wells A, Barker ME, Huling S, Feren AM, et al. Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 1991; 13: 15-20; PMID:1988335; http://dx.doi.org/10.1002/hep. 1840130104
84. Boerner JL, Demory ML, Silva C, Parsons SJ. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol 2004; 24: 7059-71; PMID:15282306; http://dx.doi.org/10.1128/MCB.24.16.7059-7071.2004
85. Haley JD, Gullick WJ. EGFR Signaling Networks in Cancer Therapy / edited by John D. Haley, William John Gullick. New York, NY: Humana Press, 2008.
86. de Oliveira JT, de Matos AJ, Santos AL, Pinto R, Gomes J, Hespanhol V, et al. Sialylation regulates galectin-3/ligand interplay during mammary tumour progression - a case of targeted uncloaking. Int J Dev Biol 2011; 55: 823-34; PMID:22161838; http://dx.doi.org/10.1387/ijdb.113359jt
87. Peschard P, Park M. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 2007; 26: 1276-85; PMID:17322912; http://dx.doi.org/10.1038/sj.onc. 1210201
88. Horm TMBB, Bitler BG, Broka DM, Louderbough JM, Schroeder JA. MUC1 Drives c-Met-Dependent Migration and Scattering. Mol Cancer Res 2012; In press; PMID:23193156; http://dx.doi.org/10.1158/1541-7786.MCR-12-0296
89. Matsubara D, Ishikawa S, Sachiko O, Aburatani H, Fukayama M, Niki T. Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas. Am J Pathol 2010; 177: 2191-204; PMID:20934974; http://dx.doi.org/10.2353/ajpath.2010.100217
90. Li YQ, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, et al. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res 2003; 1: 765-75; PMID:12939402.
91. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-16; PMID:16829981; http://dx.doi.org/10.1038/ nrm1962
92. Todorović V, Desai BV, Patterson MJS, Amargo EV, Dubash AD, Yin TF, et al. Plakoglobin regulates cell motility through Rho- and fibronectin-dependent Src signaling. J Cell Sci 2010; 123: 3576-86; PMID:20876660; http://dx.doi.org/10.1242/jcs.070391
93. Aktary Z, Chapman K, Lam L, Lo A, Ji C, Graham K, et al. Plakoglobin interacts with and increases the protein levels of metastasis suppressor Nm23-H2 and regulates the expression of Nm23-H1. Oncogene 2010; 29: 2118-29; PMID:20101217; http://dx.doi.org/10.1038/onc.2009.495
94. Ahmad R, Alam M, Rajabi H, Kufe D. The MUC1-C oncoprotein binds to the BH3 domain of the proapoptotic BAX protein and blocks BAX function. J Biol Chem 2012; 287: 20866-75; PMID:22544745; http://dx.doi.org/10.1074/jbc.M112.357293
95. Raina D, Ahmad R, Kumar S, Ren J, Yoshida K, Kharbanda S, et al. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J 2006; 25: 3774-83; PMID:16888623; http://dx.doi.org/10.1038/sj. emboj.7601263
96. Ren J, Li Y, Kufe D. Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem 2002; 277: 17616-22; PMID:11877440; http://dx.doi.org/10.1074/jbc.M200436200
97. Rajabi H, Ahmad R, Jin C, Kosugi M, Alam M, Joshi MD, et al. MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells. J Biol Chem 2012; 287: 10703-13; PMID:22318732; http://dx.doi.org/10.1074/jbc.M111.323311
98. Yuan Z, Wong S, Borrelli A, Chung MA. Downregulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Commun 2007; 362: 740-6; PMID:17764657; http://dx.doi.org/10.1016/j.bbrc.2007.08.074
99. Bernier AJ, Zhang J, Lillehoj E, Shaw AR, Gunasekara N, Hugh JC. Non-cysteine linked MUC1 cytoplasmic dimers are required for Src recruitment and ICAM-1 binding induced cell invasion. Mol Cancer 2011; 10: 93; PMID:21798038; http://dx.doi.org/10.1186/1476-4598-10-93
100. Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 1995; 55: 4000-3; PMID:7664271.
101. Sahraei M, Roy LD, Curry JM, Teresa TL, Nath S, Besmer D, et al. MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene 2012; 31: 4935-45; PMID:22266848; http://dx.doi.org/10.1038/onc.2011.651
102. Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, Cerny RL, et al. Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 2007; 67: 5201-10; PMID:17545600; http://dx.doi.org/10.1158/0008-5472.CAN-06-4647
103. Julian J, Dharmaraj N, Carson DD. MUC1 is a substrate for gamma-secretase. J Cell Biochem 2009; 108: 802-15; PMID:19711367; http://dx.doi.org/10.1002/jcb.22292
104. Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M, et al. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem 2007; 282: 19321-30; PMID:17500061; http://dx.doi.org/10.1074/jbc.M703222200
105. Wei X, Xu H, Kufe D. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res 2007; 67: 1853-8; PMID:17308127; http://dx.doi.org/10.1158/0008-5472.CAN-06-3063
106. Bitler BG, Goverdhan A, Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci 2010; 123: 1716-23; PMID:20406885; http://dx.doi.org/10.1242/jcs.062661
107. Lau SK, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, et al. EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1. PLoS One 2012; 7: e36753; PMID:22586492; http://dx.doi.org/10.1371/journal.pone.0036753
108. Baldus SE, Mönig SP, Huxel S, Landsberg S, Hanisch FG, Engelmann K, et al. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 2004; 10: 2790-6; PMID:15102686; http://dx.doi.org/10.1158/1078-0432.CCR-03- 0163
109. Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011; 30: 1449-59; PMID:21102519; http://dx.doi.org/10.1038/onc.2010.526
110. Behrens ME, Grandgenett PM, Bailey JM, Singh PK, Yi CH, Yu F, et al. The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF. Oncogene 2010; 29: 5667-77; PMID:20697347; http://dx.doi.org/10.1038/onc.2010.327
111. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998; 4: 1449-52; PMID:9846587; http://dx.doi.org/10.1038/4042
112. Bitler BG, Schroeder JA. Anti-cancer therapies that utilize cell penetrating peptides. Recent Pat Anticancer Drug Discov 2010; 5: 99-108; PMID:19961434; http://dx.doi.org/10.2174/157489210790936252
113. Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A, et al. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res 2009; 15: 100-9; PMID:19118037; http://dx.doi.org/10.1158/1078-0432.CCR-08-1745
114. Zhang L, Gallup M, Zlock L, Basbaum C, Finkbeiner WE, McNamara NA. Cigarette smoke disrupts the integrity of airway adherens junctions through the aberrant interaction of p120-catenin with the cytoplasmic tail of MUC1. J Pathol 2012; In press; PMID:22833523; http://dx.doi.org/10.1002/path.4070
115. Klinge CM, Radde BN, Imbert-Fernandez Y, Teng Y, Ivanova MM, Abner SM, et al. Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells. Mol Cancer Ther 2011; 10: 2062-71; PMID:21862684; http://dx.doi.org/10.1158/1535- 7163.MCT-11-0381
116. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther 2011; 10: 806-16; PMID:21421804; http://dx.doi.org/10.1158/1535- 7163.MCT-10-1050
117. Yin L, Kufe D. MUC1-C Oncoprotein Blocks Terminal Differentiation of Chronic Myelogenous Leukemia Cells by a ROS-Mediated Mechanism. Genes Cancer 2011; 2: 56-64; PMID:21643558; http://dx.doi.org/10.1177/1947601911405044
118. Hisatsune A, Nakayama H, Kawasaki M, Horie I, Miyata T, Isohama Y, et al. Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells. Biochem Biophys Res Commun 2011; 405: 377-81; PMID:21219855; http://dx.doi.org/10.1016/ j.bbrc.2011.01.029
119. Schettini J, Kidiyoor A, Besmer DM, Tinder TL, Roy LD, Lustgarten J, et al. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. Cancer Immunol Immunother 2012; 61: 2055-65; PMID:22543528; http://dx.doi.org/10.1007/s00262-012-1264-y
120. Wang L, Chen H, Pourgholami MH, Beretov J, Hao J, Chao H, et al. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One 2011; 6: e24405; PMID:21931707; http://dx.doi.org/10.1371/journal.pone.0024405
121. Oei AL, Moreno M, Verheijen RH, Sweep FC, Thomas CM, Massuger LF, et al. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int J Cancer 2008; 123: 1848-53; PMID:18661524; http://dx.doi.org/10.1002/ijc.23725
122. Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 2006; 8: R27; PMID:16776849; http://dx.doi.org/10.1186/bcr1505
123. Kamata M, Denda-Nagai K, Kubota N, Aida S, Takeda K, Irimura T. Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases. Clin Exp Metastasis 2002; 19: 689-96; PMID:12553374; http://dx.doi.org/10.1023/A:1021332932531
124. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A 2012; 109: 261-6; PMID:22171012; http://dx.doi.org/10. 1073/pnas.1115166109
125. Kovjazin R, Volovitz I, Kundel Y, Rosenbaum E, Medalia G, Horn G, et al. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine 2011; 29: 4676-86; PMID:21570434; http://dx.doi.org/10.1016/j.vaccine.2011.04.103
126. McCarthy N. Running a Muc1. Nat Rev Cancer 2012; 12: 317; http://dx.doi.org/10.1038/nrc3274
127. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331: 1559-64; PMID:21436443; http://dx.doi.org/10.1126/science.1203543